Y-Intercept (HK)
CLYM icon

Y-Intercept (HK)’s Climb Bio CLYM Stock Holding History

Y-Intercept (HK)’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$706K Buy
+61,553
New +$858K 0.02% 1157
2025
Q3 		– Sell
-127,952
Closed -$159K – 2153
2025
Q2 		$159K Buy
+127,952
New +$159K ﹤0.01% 1491

Other funds holding CLYM

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Nan Fung Trinity
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.04B AUM 32.17% 1-Year Est. Return
Jefferies Financial Group
Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.2B AUM 25.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Oppenheimer & Co
Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Y-Intercept (HK)'s CLYM Position: Q3 2026 in Review

Y-Intercept (HK) opened a new position in Climb Bio (CLYM) in Q3 2026: 61,553 shares worth $706K. The stake represents 0.02% of the portfolio and ranks #1157 among its holdings. This is a return to the name: Y-Intercept (HK) previously reported a position in CLYM as recently as Q2 2025.

Y-Intercept (HK) first reported a position in CLYM in Q2 2025 and has held it in 2 quarters since. 28 funds tracked by Wall St. Rank hold CLYM as of Q3 2026.

  • Y-Intercept (HK) held 61,553 shares of Climb Bio worth $706K as of Q3 2026.
  • Climb Bio was a new Y-Intercept (HK) position in Q3 2026.
  • Climb Bio made up 0.02% of Y-Intercept (HK)'s portfolio in Q3 2026, its #1157 holding.
  • Y-Intercept (HK) first reported a position in Climb Bio in Q2 2025 and has held it in 2 quarters since.
  • 28 funds tracked by Wall St. Rank held Climb Bio as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.